Status:
TERMINATED
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
Lead Sponsor:
GlaxoSmithKline
Conditions:
Heart Failure, Congestive and Microalbuminuria
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This study was designed to determine whether COREG MR is more effective than TOPROL-XL in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbumi...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Documented history of hypertension.
- Must have been taking an ACE (angiotensin converting enzyme) inhibitor either alone or as part of an antihypertensive regimen for at least 8 weeks.
- Persistent microalbuminuria.
- Exclusion criteria:
- History of heart attack, stroke, congestive heart failure, arrhythmia, type 1 or uncontrolled type 2 diabetes mellitus, liver or renal disease.
- Has been taking any non-ocular beta-blockers for any indication within three months prior to Pre-screening.
Exclusion
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
1220 Patients enrolled
Trial Details
Trial ID
NCT00123903
Start Date
July 1 2005
End Date
May 1 2006
Last Update
January 18 2017
Active Locations (94)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Birmingham, Alabama, United States, 35213
2
GSK Investigational Site
Mobile, Alabama, United States, 36617
3
GSK Investigational Site
Phoenix, Arizona, United States, 85023
4
GSK Investigational Site
Fullerton, California, United States, 92835